High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology

Based on emerging data and current knowledge regarding high-risk human papillomavirus (hrHPV) testing as a primary screening for cervical cancer, the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology support the following scientific facts: • Compared to cytol...

Full description

Saved in:
Bibliographic Details
Published inJournal of gynecologic oncology Vol. 31; no. 1; p. e31
Main Authors Kong, Tae Wook, Kim, Miseon, Kim, Young Han, Kim, Yong Beom, Kim, Jayeon, Kim, Jae Weon, Park, Mi Hye, Park, Joo Hyun, Rhee, Jeong Ho, Lim, Myong Cheol, Hong, Joon Seok
Format Journal Article
LanguageEnglish
Published Korea (South) Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 01.01.2020
대한부인종양학회
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Based on emerging data and current knowledge regarding high-risk human papillomavirus (hrHPV) testing as a primary screening for cervical cancer, the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology support the following scientific facts: • Compared to cytology, hrHPV screening has higher sensitivity and detects more cases of high-grade cervical intraepithelial neoplasia. • Qualified hrHPV testing can be considered as an alternative primary screening for cervical cancer to the current cytology method. • The starting age of primary hrHPV screening should not be before 25 years because of possible overtreatment in this age, which has a high human papillomavirus (HPV) prevalence but rarely progresses to cancer. The screening interval should be no sooner than every 3 years and no longer than every 5 years. • Before the introduction of hrHPV screening in Korea, research into comparative effectiveness of primary hrHPV screening for cervical cancer should be conducted to determine the appropriate HPV assay, starting age, and screening interval.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This statement asserts the official position of the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology and is published jointly in the Obstetrics & Gynecologic Science and the Journal of Gynecologic Oncology. It has no legal and or political validity for clinical decisions.
https://doi.org/10.3802/jgo.2020.31.e31
ISSN:2005-0380
2005-0399
DOI:10.3802/jgo.2020.31.e31